eng Oriental Scientific Publishing Company Biosciences Biotechnology Research Asia 0973-1245 2015-12-25 12 3 2405 2410 10.13005/bbra/1917 4130 article Majid Asadi-Ghalehni 1 Mohamad Javad Rasaee 2 Masoud Javanmardi 2 Saeed Khalili 2 Mohsen Mohamadi 2 Farnaz Fatemi 1 Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, I.R. Iran The epidermal growth factor receptor (EGFR) belongs to the ErbB family of receptor tyrosine kinases (RTK). EGFR over expressed in different cancers like neck, lung and breast. Various approaches have been used to activate the immune system against EGFR⁺ cancer such as vaccine therapy. Herein a recombinant fusion peptide composed of EGFR mimotope and L2 domain of EGFR designed. Using in silico studies the potency of the peptide as a vaccine evaluated. This peptide was then cloned into an expression vector and expressed in E. Coli. The ELISA results of the purified peptide against anti EGFR antibodies showed that this peptide could be functional as a vaccine candidate against EGFR-positive tumors. https://www.biotech-asia.org/vol12no3/in-silico-and-in-vitro-evaluation-of-a-recombinant-fusion-peptide-as-a-novel-candidate-vaccine-for-egfr-positive-tumors/ epidermal; receptor; kinases; Evaluation